$KMB · KIMBERLY CLARK CORP SEC Filings
Position Tracker tracks 5 SEC EDGAR filings for KIMBERLY CLARK CORP ($KMB) from October 29, 2026 through November 5, 2026, including 0 Form 10-K annual reports, 1 Form 10-Q quarterly earnings reports, 4 Form 8-K current event disclosures, and 0 Form 4 insider equity transactions. Select any filing below to read the full AI summary, key financial takeaways, and original SEC.gov document.
$KMB 10-Q — KIMBERLY CLARK CORP
Kimberly-Clark is simultaneously executing a transformative Kenvue acquisition and an IFP divestiture, reshaping its portfolio while core organic sales decline.
$KMB 8-K — KIMBERLY CLARK CORP
Kimberly-Clark's first quarter after completing the Kenvue/IFP transaction shows a 17.2% adjusted EPS gain but a China-driven organic sales decline, with the 2026 outlook reaffi…
$KMB 8-K — KIMBERLY CLARK CORP
The filing confirms completion of a transformative merger and a $7B debt assumption/exchange, reshaping Kimberly-Clark's capital structure and consumer health footprint.
$KMB 8-K — KIMBERLY CLARK CORP
This is one of the largest consumer health M&A deals in recent history, creating a $31.6B-revenue giant with 10 billion-dollar brands and a clear $2.1B synergy roadmap that will…
$KMB 8-K — KIMBERLY CLARK CORP
The $4.9 billion debt raise fully funds the Kenvue acquisition and retires bridge financing, but the special mandatory redemption clause creates a hard deadline with a ~$49 mill…